Related Experiment Videos
Antiestrogens, antiandrogens
J Borvendég1, I Hermann, O Csuka
1National Institute of Pharmacy, Budapest, Hungary.
Acta Physiologica Hungarica
|January 1, 1996
Summary
Researchers identified potent antiestrogenic and antiandrogenic compounds. Panomifene showed strong antiestrogenic activity, while a di-imidazolil derivative inhibited androgen biosynthesis more effectively than ketoconazole.
Area of Science:
- Medicinal Chemistry
- Endocrinology
Background:
- Development of novel antiestrogenic and antiandrogenic agents is crucial for treating hormone-dependent diseases.
- Existing therapies have limitations, necessitating the search for more effective compounds.
Purpose of the Study:
- To discover and characterize new antiestrogenic and antiandrogenic chemical structures.
- To evaluate the efficacy of novel triphenyl-alkene, indole, and imidazole derivatives.
Main Methods:
- Screening of triphenyl-alkene derivatives for antiestrogenic activity.
- Synthesis and evaluation of indole and imidazole derivatives for antiandrogenic properties.
- In vitro and in vivo assays to assess compound efficacy and mechanism of action.
Main Results:
- Panomifene (EGIS-5660), a triphenyl-alkene derivative, demonstrated significant antiestrogenic activity by binding to estrogen receptors and inhibiting mammary tumor growth.
- A di-imidazolil derivative, GYK1-24479, effectively inhibited androgen (testosterone and androstenedione) biosynthesis in vitro and in vivo.
- GYK1-24479 exhibited superior antiandrogenic activity compared to ketoconazole.
Conclusions:
- Panomifene is a promising antiestrogenic compound with potential therapeutic applications.
- The novel di-imidazolil derivative GYK1-24479 represents a potent antiandrogenic agent for further investigation.
- These findings contribute to the development of new strategies for hormone-related cancer treatment.